Global Gene Therapy and CRISPR Market Shows Billion Dollar Growth with Novartis Zolgensma 1.2 Billion Sarepta Elevidys 611 Million and Emerging CRISPR Collaborations 20 Million

Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and CRISPR therapeutics market, highlighting key company performance, pipeline ...
STAT

The race to build better CRISPR delivery vehicles is heating up

If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...
Hosted on MSN

Q&A: How organoids could make gene therapy trials safer by identifying hidden risks early on

Ryuji Morizane, MD, Ph.D., of the Department of Medicine at Massachusetts General Hospital, is the senior/corresponding author of a new paper published in Signal Transduction and Targeted Therapy, ...
WGHP

Andelyn Biosciences AAV Curator® Platform Used to Manufacture Clinical Grade Viral Vector for FDA-Authorized First-In-World Universal Donor CRISPR/AAV Transduced CAR-NK Cells

COLUMBUS, Ohio, May 6, 2025 /PRNewswire/ -- Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has manufactured ...
Forbes

CRISPR: From Discovery To Clinic—And Charting A Path Forward

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
Seeking Alpha

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain ...